Q-REstrain by RGCC for Lyme Disease, Tick-Borne Infections, and Chronic Viral Burden

A patient guide to Q-REstrain (formerly known as SOT) as a precision therapy within a terrain-based, bioenergetic approach to chronic Lyme disease and complex chronic infection.

A precision therapy within a terrain-based Lyme treatment model

Many patients with chronic Lyme disease, tick-borne infections, chronic viral reactivation, mold illness, mast cell activation, chronic fatigue, brain fog, pain, and immune dysregulation feel as though they have tried everything. They may have used antibiotics, herbal antimicrobials, binders, detoxification protocols, immune support, dietary changes, limbic system retraining, ozone therapy, hyperbaric oxygen, neural therapy, and numerous supplements. Some patients improve dramatically. Others improve only partially, relapse when treatment stops, or continue to feel as though their immune system is constantly fighting something it cannot fully resolve.

At Tree of Light Health, we view chronic Lyme disease and co-infections through a terrain-based, bioenergetic lens. We do not view chronic Lyme disease as a simple "one infection, one medication" problem. Instead, we evaluate the full terrain - including immune function, toxic burden, mold exposure, nervous system regulation, gut health, dental stressors, mitochondrial function, hormone balance, biofilms, lymphatic drainage, and the body's ability to clear infections.

This broader philosophy is explained in more detail in our companion article, A Terrain-Based, Bioenergetic Approach to Chronic Lyme Disease and Coinfections.

Q-REstrain by RGCC, previously known as Supportive Oligonucleotide Therapy or SOT, can be thought of as one advanced precision tool that may fit into this larger Lyme and co-infection framework. In our practice, we generally consider Q-REstrain when advanced testing, clinical history, and biofeedback assessment suggest that a specific infection or virus remains a major unresolved burden despite foundational work.

In other words, Q-REstrain is usually not our first step. It is more often considered when the terrain has been supported, but the immune system still appears unable to fully clear or regulate a specific microbial or viral burden.

The mold layer: why this may determine whether Q-REstrain works well

In our clinical experience, mold is not a footnote in chronic Lyme disease. It is often one of the central reasons patients remain stuck. For a deeper discussion of mold as a driver of chronic illness, see our article on mold and biotoxin illness and our overview of Chronic Inflammatory Response Syndrome (CIRS).

This point cannot be overstated. A patient may have real Borrelia, Bartonella, Babesia, or viral burden, but if they are living or working in a moldy environment, their immune system may remain stuck in a chronic inflammatory alarm state. In that state, the body may not regulate inflammation well, detoxification may be impaired, mast cells may be overactive, the nervous system may be hypervigilant, and the patient may react strongly to even gentle antimicrobial support.

When mold is active, the immune system can become so dysregulated that even a highly targeted therapy may not create the expected clinical response. Q-REstrain may reduce a specific infectious burden, but the body still has to process inflammatory debris, clear toxins, regulate cytokines, calm mast cells, move bile, drain lymphatics, and restore immune tolerance. Mold can interfere with all of these steps.

For this reason, we often evaluate mold and mycotoxin burden before moving into more advanced infection therapies. In some patients, mold must be addressed first. In others, we may work on mold and infection in parallel, but the mold layer cannot be ignored.

In practical terms, this means that we do not want to send a patient into Q-REstrain while ignoring a major mold exposure. If the mold layer is still active, the patient may spend significant money on an advanced therapy but get only a partial response. In many cases, the best way to make Q-REstrain more effective is to first improve the terrain.

What is Q-REstrain?

Q-REstrain by RGCC is the current name for the personalized oligonucleotide technology produced by RGCC, the laboratory group in Greece that designs this therapy. It was previously known as Supportive Oligonucleotide Therapy, or SOT. The science is the same — only the name has changed. Q-REstrain is designed around very specific microbial, viral, or cellular targets.

Q-REstrain is not a general antibiotic, antiviral, immune booster, or detox therapy. It is a highly targeted therapy designed around a specific organism or genetic sequence.

The list of organisms RGCC can currently produce Q-REstrain for is updated regularly. Below are the targets currently available, organized into tick-borne organisms and chronic viral targets.

Tick-borne organisms available for Q-REstrain

Chronic viral targets available for Q-REstrain

RGCC updates the available Q-REstrain target list regularly. Availability for any specific organism is confirmed at the time the laboratory attempts to design the therapy.

Why patients are interested in Q-REstrain

Many patients with chronic Lyme disease and chronic viral reactivation are not dealing with a simple acute infection. They are often dealing with a long-standing immune burden that has become layered into the nervous system, detoxification pathways, mitochondria, hormones, lymphatic system, gut, and inflammatory response.

In these cases, the question is not simply, "Can we kill the infection?" The deeper question is, "Can we help the immune system regain enough clarity, strength, and regulation to keep these organisms under control again?"

In a healthier terrain, the immune system may be able to recognize, contain, and regulate organisms such as Borrelia, Bartonella, Babesia, EBV, HHV-6, and other chronic infectious burdens. But when the terrain is compromised by mold toxins, heavy metals, chronic stress, poor sleep, nutrient depletion, mitochondrial dysfunction, gut inflammation, dental infections, biofilms, mast cell activation, or chronic sympathetic nervous system overdrive, the immune system may lose its ability to maintain control.

Q-REstrain is being explored because it offers a different therapeutic concept. Instead of broadly suppressing or killing microbes, Q-REstrain attempts to interfere with the organism's ability to replicate or carry out essential functions by targeting its messenger RNA. In other words, it is designed to "silence" a specific genetic message that the organism needs in order to continue functioning.

A helpful way to think about Q-REstrain is that it may act like a form of "birth control for bugs." It does not work like a traditional antibiotic that broadly attacks bacteria. Instead, it is designed to bind to a very specific genetic message associated with the target organism, potentially reducing its ability to reproduce or maintain pathogenic activity.

How Q-REstrain works: the basic biology

An oligonucleotide is a short sequence of nucleic acids - the building blocks of DNA and RNA. The basic idea is this:

Bacteria, viruses, and human cells all rely on genetic instructions to carry out biological functions. Q-REstrain is designed to create a complementary sequence that binds to a specific messenger RNA target associated with a pathogen. Once bound, that messenger RNA can no longer do its job properly. In practical terms, the goal is to interfere with the organism's ability to replicate, survive, or express key proteins.

A simple analogy is this: imagine the organism has a key instruction manual it needs in order to keep copying itself. Q-REstrain is designed to bind to a specific page of that instruction manual so the organism cannot use it properly.

This mechanism belongs to a broader family of therapies known as antisense oligonucleotide therapies. The same general principle - using a short, complementary genetic sequence to block a target messenger RNA - has been studied and used in mainstream medicine for several other conditions.

Q-REstrain is not a generic Lyme treatment

This is one of the most important concepts for patients to understand. Q-REstrain is not a general treatment for "Lyme disease." It is a highly specific therapy designed around a specific organism.

For example, if a patient has evidence of multiple Borrelia species, Bartonella, Babesia, EBV, and HHV-6, these are not all treated with one generic Q-REstrain. Each organism has to be considered separately.

This is why Q-REstrain should not be approached casually. It requires careful testing, clinical judgment, preparation, and terrain support.

The terrain matters as much as the target

One of the biggest mistakes in chronic Lyme treatment is assuming that the infection is the only problem. In our experience, chronic Lyme disease and co-infections often persist because the internal terrain has become biologically compromised.

Two patients with similar Lyme test results can respond very differently to treatment. One may tolerate antimicrobials well and improve quickly. Another may flare dramatically from tiny doses. Another may improve briefly and then relapse. Another may only improve once mold exposure is addressed. Another may not tolerate any antimicrobial work until the nervous system is calmed and mast cells are stabilized.

Q-REstrain may be highly targeted, but the patient's terrain determines how well the body can respond to that target.

Our testing process before Q-REstrain

Before a Q-REstrain can be requested, we need evidence that the organism is present or immunologically relevant. For Lyme and tick-borne infections, we often begin with advanced testing such as the Vibrant Tickborne 2.0 panel. This gives us a broader view of possible Borrelia species, Bartonella, Babesia, Ehrlichia, Anaplasma, Rickettsia, and other vector-borne organisms.

Depending on the case, we may also consider additional testing. Rather than listing every possible lab, it is helpful to think in categories:

The goal is not simply to collect abnormal labs. The goal is to build a coherent map of what is actually driving the patient's symptoms.

The role of ART, CBT, and FCT in refining Q-REstrain candidates

At Tree of Light Health, we do not rely only on lab testing. We also use advanced biofeedback and energetic assessment techniques to further refine which organisms appear to be creating the greatest biological stress in the body.

Advanced Lyme testing may show us what the immune system has been exposed to. ART, CBT, and FCT may help us understand which findings are most relevant now and how the body is prioritizing them. For example, a lab test may show Borrelia, Bartonella, Babesia, EBV, and HHV-6, but biofeedback may suggest that Bartonella, Babesia, or mold is the dominant active stressor.

Reducing pathogen load before Q-REstrain: how EBOO and TruDose PRP fit in

One of the most important clinical refinements we have made in our Q-REstrain protocols involves what comes before the therapy. We have found that reducing the overall pathogen and inflammatory load before Q-REstrain often improves outcomes — and in many cases reduces the total number of Q-REstrains a patient ultimately needs.

Two of our most powerful tools for this are EBOO and TruDose PRP.

Not every patient needs this full sequence. Some are ready for Q-REstrain after foundational terrain work. Others, particularly those with high pathogen burden, multiple co-infections, or limited tolerance for die-off, may benefit greatly from EBOO and TruDose PRP first.

Q-REstrain is generally reserved for more compromised or difficult cases

In our practice, Q-REstrain is not usually the first tool we reach for. Many patients can make significant progress with a comprehensive terrain-based approach that may include antimicrobial herbs, immune support, detoxification, binders, nervous system regulation, drainage therapies, mold avoidance, mitochondrial support, ozone therapy, hyperbaric oxygen therapy, neural therapy, IASIS microcurrent neurofeedback, ART, CBT, FCT, and other individualized interventions.

Q-REstrain is generally reserved for patients who appear to have a more significant compromise in immune function or patients in whom we simply cannot seem to clear or regulate the infection using our usual techniques.

In these cases, Q-REstrain may provide a more precise way to reduce infectious burden and give the immune system a better chance to regain control.

The Q-REstrain design process

Once we identify a potential target through testing, a blood sample is sent through the specialty laboratory process. RGCC in Greece then attempts to confirm the organism from the patient's sample. This confirmation step is very important.

The lab is not simply pulling a generic Lyme Q-REstrain from a shelf. The goal is to identify the organism and design an oligonucleotide sequence that is specific to that patient's target. If the outside testing suggests Borrelia burgdorferi, for example, the RGCC laboratory still attempts to confirm that organism before producing the therapy. If the lab cannot confirm the organism, the Q-REstrain may not be made.

Clinically, we view this as a strength of the process. It helps reduce the chance of treating something that cannot be confirmed through the laboratory's molecular process.

How we choose which infection to target first

Many complex patients have more than one positive finding. It is common to see evidence of Borrelia, Bartonella, Babesia, EBV, HHV-6, mold-related immune activation, and other inflammatory burdens in the same person. This creates an important question: Where do we start?

This is where clinical experience matters. We are not simply treating a lab report. We are treating a person.

Why we do not usually treat every positive organism at once

Q-REstrain is highly specific. That is one of its strengths, but also one of its limitations. If someone has multiple Borrelia species, Bartonella species, Babesia species, and viruses, it may not be realistic or wise to do Q-REstrain for everything at once.

Too much die-off, immune stimulation, or inflammatory debris can overwhelm the body, especially in sensitive patients. This is particularly true in patients with mold illness, MCAS, dysautonomia, constipation, poor detoxification, severe fatigue, or neuroinflammation.

RGCC has clear dosing guidelines for Q-REstrain based on the target type:

For patients with chronic Lyme disease, tick-borne co-infections, or chronic viral reactivation, this means up to nine Q-REstrains per year are possible, with at least three weeks between doses. This provides meaningful flexibility for complex cases involving multiple targets, but it also requires careful planning and prioritization — especially when several organisms are clinically relevant.

More is not automatically better. The exact number, timing, and sequencing depends on the patient's response, symptom burden, level of resilience, detoxification capacity, and how the immune system is reorganizing between doses. Our goal is not to "blast" the body. Our goal is to reduce infectious and inflammatory burden in a way the patient can tolerate.

This is also where pre-treatment with EBOO and TruDose PRP often pays off — by reducing pathogen load and supporting immune recalibration before Q-REstrain, we frequently find that patients need fewer total Q-REstrains to reach their clinical goals.

Preparing for Q-REstrain

Preparation is one of the most important parts of the process. We want the body to be able to recognize, process, and clear microbial debris without triggering an excessive inflammatory response.

If a patient is constipated, living in active mold, highly reactive to supplements, or sleeping poorly, we often need to stabilize those areas before moving into Q-REstrain.

What may need to be stopped before testing or Q-REstrain?

Because Q-REstrain is designed around identifying and targeting an organism, we generally want the organism to be detectable. If a patient is aggressively suppressing or killing that organism with antimicrobials right before the blood draw, the lab may have a harder time confirming it.

Depending on the case, we may recommend pausing certain pathogen-directed therapies before the Q-REstrain blood draw. This may include antibiotics, antimicrobial herbs, antivirals, methylene blue, high-dose IV vitamin C, ozone therapies, or other therapies that may suppress the target.

This does not mean every supportive therapy must be stopped. Nutritional support, vitamin D, minerals, binders, gentle detoxification, nervous system support, and immune-regulating therapies may often continue depending on the case. The goal is to avoid confusing the testing process and to avoid overwhelming die-off immediately after the infusion.

The Q-REstrain administration process

Q-REstrain is administered intravenously in the office. The process is usually straightforward and does not typically feel like a long IV therapy day. The Q-REstrain is generally reconstituted and administered through an IV, often followed by a small IV bag to help flush the therapy through.

The exact protocol depends on the patient's medical history, allergies, mast cell sensitivity, medications, and overall fragility. Some patients feel completely normal afterward. Some feel slightly better initially. Others may develop delayed die-off symptoms over the following days or weeks.

What is a Herxheimer reaction?

A Herxheimer reaction, sometimes called "Herxing," refers to a temporary symptom flare that can occur when microbes are disrupted and the immune system has to process inflammatory debris.

With Q-REstrain, Herxheimer reactions are not always immediate. Some patients feel nothing at first and then begin to notice changes later. Others may feel better within days. Others may have a temporary flare before improvement.

This is one reason we like objective tracking. Symptom questionnaires, Horowitz MSIDS scoring, fatigue scales, pain scales, sleep tracking, and functional goals can help us determine whether the therapy is helping.

How long does Q-REstrain last?

Clinically, Q-REstrain is often discussed as remaining active for several months. The molecule is engineered with stealth-like properties that help it evade rapid breakdown by the body's RNase enzymes, allowing it to remain biologically active in the bloodstream for an extended period — commonly cited as approximately 16 to 20 weeks per dose, and possibly longer. This does not mean that every patient needs repeated Q-REstrain indefinitely. Some patients may need one Q-REstrain for one dominant target. Others may need a sequence of Q-REstrains over time for different organisms.

Some patients may need additional work on mold, detoxification, immune regulation, or nervous system healing before another Q-REstrain makes sense. We generally reassess based on clinical response, symptom tracking, and follow-up testing when appropriate.

Q-REstrain for chronic viral reactivation

Chronic viral reactivation is common in complex chronic illness. EBV, HHV-6, HSV, CMV, VZV, and other viruses can become more active when the immune system is under chronic stress from mold, Lyme, trauma, poor sleep, nutrient depletion, heavy metals, gut inflammation, or other chronic burdens.

Q-REstrain may be considered when viral testing suggests clinically relevant viral activity and when the patient's symptoms fit the picture. However, we are careful not to chase every abnormal viral marker. Many adults have positive IgG antibodies to common herpesviruses. A positive past-exposure marker does not automatically mean the virus is the primary driver of symptoms.

Who may be a good candidate for Q-REstrain?

Q-REstrain may be considered for patients who have evidence of Lyme disease, tick-borne infection, or chronic viral burden that fits the clinical picture, especially when symptoms persist despite foundational care.

Who may not be a good candidate?

Q-REstrain is not for everyone. Possible reasons for caution may include pregnancy, breastfeeding, severe uncontrolled mast cell activation, severe constipation or blocked detoxification, active mold exposure, severe dysautonomia, extreme fragility, advanced neurodegenerative illness, unstable medical conditions, poor ability to tolerate die-off, or lack of support at home.

We use extra caution when a patient is living in active mold exposure, sleeping poorly, highly reactive to supplements, or stuck in a severe sympathetic fight-or-flight state. In these cases, preparation may be more important than rushing into Q-REstrain.

What Q-REstrain is not

Q-REstrain is not a guaranteed cure. It is not a replacement for acute Lyme treatment when antibiotics are indicated. It is not a substitute for emergency care, cardiology evaluation, neurology evaluation, infectious disease care, or appropriate conventional medical treatment when those are needed.

It is not a stand-alone solution for mold illness, MCAS, trauma physiology, gut dysfunction, or environmental exposure. It is also not a broad-spectrum antimicrobial. If the Q-REstrain is designed for Borrelia burgdorferi, it is not automatically treating Bartonella, Babesia, EBV, mold, parasites, or fungal overgrowth.

Why Q-REstrain sometimes does not work

When Q-REstrain does not appear to help, we ask whether the correct target was chosen, whether that target was clinically active or merely immune memory, whether another infection was dominant, whether mold exposure was still active, whether MCAS was driving symptoms more than infection, and whether detoxification pathways were too blocked to tolerate deeper work.

We also ask whether the nervous system was stuck in sympathetic overdrive, whether sleep apnea, hypoxia, hormone depletion, or mitochondrial dysfunction was overlooked, whether dental or sinus infections were present, and whether the terrain was too compromised for the immune system to respond properly.

This is why our approach is not simply "test, infuse, done." We want to understand the terrain, the immune system, the nervous system, and the patient's resilience.

Our approach at Tree of Light Health

At Tree of Light Health, we use Q-REstrain as part of a broader integrative, functional, and bioenergetic medicine framework.

Educational resources

For a short, clear animation explaining the basic mechanism of antisense oligonucleotide therapies — the same general principle Q-REstrain uses to silence a target organism's messenger RNA — we recommend:

How antisense drugs work (3-minute animation)

For a deeper discussion of Q-REstrain (referred to in the interview by its earlier name, SOT), Lyme disease, vector-borne infections, viruses, testing, safety, and clinical decision-making, we recommend watching this interview with Dr. Clayton Bell on the BetterHealthGuy podcast:

Supportive Oligonucleotide Therapy - SOT - with Dr. Clayton Bell

For more on our broader philosophy around chronic Lyme disease, co-infections, biofilms, mold, immune dysfunction, terrain medicine, and bioenergetic assessment, we recommend reading:

A Terrain-Based, Bioenergetic Approach to Chronic Lyme Disease and Coinfections

Related articles on the Tree of Light Health website:

• Mold and Biotoxin Illness
• Chronic Inflammatory Response Syndrome (CIRS)
• EBOO and Advanced Ozone Therapies
• TruDose IV Platelet Therapy (PRP)
• Hyperbaric Oxygen Therapy (HBOT)
• IASIS Microcurrent Neurofeedback
• Autonomic Response Technique (ART)
• Cranial Biotic Technique (CBT)
• Field Control Therapy (FCT)

Final thoughts

Q-REstrain represents an exciting direction in personalized medicine: a highly specific, molecularly targeted approach aimed at reducing the burden of chronic infections by interfering with microbial or viral replication pathways. For the right patient, it may be a valuable tool.

But it works best when used thoughtfully and within a broader terrain-based approach. Chronic Lyme disease and viral reactivation rarely exist in isolation. The immune system, detoxification pathways, mold exposure, mast cells, mitochondria, hormones, nervous system, emotional stress physiology, gut health, dental stressors, biofilms, and environmental exposures all influence whether a patient can respond well.

Our goal is not simply to "kill bugs." Our goal is to help the body regain regulation, resilience, and vitality. For patients who have been stuck for years with chronic Lyme symptoms, tick-borne infections, viral reactivation, brain fog, fatigue, pain, and inflammatory flares, Q-REstrain may offer another layer of precision support within a comprehensive root-cause plan.